Our top pick for
Akcea Therapeutics, Inc is a biotechnology business based in the US. Akcea Therapeutics shares (AKCA) are listed on the NASDAQ and all prices are listed in US Dollars. Akcea Therapeutics employs 294 staff and has a trailing 12-month revenue of around USD$336.6 million.
|52-week range||USD$8 - USD$20.94|
|50-day moving average||USD$18.1503|
|200-day moving average||USD$15.0153|
|Wall St. target price||USD$28.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.286|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Akcea Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Akcea Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Akcea Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 40x. In other words, Akcea Therapeutics shares trade at around 40x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Akcea Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$44.7 million.
The EBITDA is a measure of a Akcea Therapeutics's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$336.6 million|
|Gross profit TTM||USD$185.7 million|
|Return on assets TTM||-5.95%|
|Return on equity TTM||-9.8%|
|Market capitalisation||USD$1.8 billion|
TTM: trailing 12 months
There are currently 759,276 Akcea Therapeutics shares held short by investors – that's known as Akcea Therapeutics's "short interest". This figure is 34.8% down from 1.2 million last month.
There are a few different ways that this level of interest in shorting Akcea Therapeutics shares can be evaluated.
Akcea Therapeutics's "short interest ratio" (SIR) is the quantity of Akcea Therapeutics shares currently shorted divided by the average quantity of Akcea Therapeutics shares traded daily (recently around 1.1 million). Akcea Therapeutics's SIR currently stands at 0.68. In other words for every 100,000 Akcea Therapeutics shares traded daily on the market, roughly 680 shares are currently held short.
However Akcea Therapeutics's short interest can also be evaluated against the total number of Akcea Therapeutics shares, or, against the total number of tradable Akcea Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Akcea Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Akcea Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0597% of the tradable shares (for every 100,000 tradable Akcea Therapeutics shares, roughly 60 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Akcea Therapeutics.
Find out more about how you can short Akcea Therapeutics stock.
We're not expecting Akcea Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Akcea Therapeutics's shares have ranged in value from as little as $8 up to $20.94. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Akcea Therapeutics's is 1.4434. This would suggest that Akcea Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, an antisense medicine designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome, as well as is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of homozygous familial hypercholesterolemia; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. is a subsidiary of Ionis Pharmaceuticals, Inc.
Everything we know about the DataRobot IPO, plus information on how to buy in.
Everything we know about the Bird Rides IPO, plus information on how to buy in.
Everything we know about the Universe Pharmaceuticals IPO, plus information on how to buy in.
Steps to owning and managing AKR, with 24-hour and historical pricing before you buy.
Steps to owning and managing WPP, with 24-hour and historical pricing before you buy.
Steps to owning and managing WY, with 24-hour and historical pricing before you buy.
Steps to owning and managing WEYS, with 24-hour and historical pricing before you buy.
Steps to owning and managing WAB, with 24-hour and historical pricing before you buy.
Steps to owning and managing VSH, with 24-hour and historical pricing before you buy.
Steps to owning and managing VLGEA, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.